RESUMEN
The role of Ann Arbor staging in determining treatment intensity after achieving a negative positron emission tomography (PET) has not been established in classical Hodgkin lymphoma (cHL). Patients with stage I-IV cHL, received three cycles of ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) and an interim PET scan (PET3). PET3-negative patients received no further therapy. PET3-positive patients received three additional cycles of ABVD plus involved-field radiation therapy or salvage chemotherapy, if refractory to ABVD, and were re-evaluated by PET scan (PET6). Study endpoints were 3-year progression-free survival (PFS) and overall survival (OS) rates. Two hundred and thirty-nine patients with early-stage and 138 with advanced-stage were evaluable. Overall, 260 patients (70%) were PET3-negative and had higher 3-year PFS (90% vs. 65%; P < 0·0001) and OS (98% vs. 92%; P = 0·007) rates than PET3-positive patients. All PET3-negative patients, regardless of disease stage at diagnosis, achieved similarly good PFS (90-91%; P = 0·76) and OS (97-99%). The only independent prognostic factor for PFS was PET3-negativity (Hazard ratio 3·8; 95% confidence interval 2·4-6·3; P < 0·0001). This study suggests that cHL patients who achieve a negative PET3 following ABVD have an excellent outcome, regardless of stage at diagnosis. An appropriately powered, phase III trial will be necessary to confirm these findings.
Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Enfermedad de Hodgkin/diagnóstico por imagen , Enfermedad de Hodgkin/tratamiento farmacológico , Tomografía de Emisión de Positrones/métodos , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Protocolos de Quimioterapia Combinada Antineoplásica/farmacología , Bleomicina/farmacología , Bleomicina/uso terapéutico , Dacarbazina/farmacología , Dacarbazina/uso terapéutico , Doxorrubicina/farmacología , Doxorrubicina/uso terapéutico , Femenino , Enfermedad de Hodgkin/patología , Humanos , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Análisis de Supervivencia , Vinblastina/farmacología , Vinblastina/uso terapéutico , Adulto JovenRESUMEN
Even though over more than 20 years researchers link different moods and immune function, since 1995 biologic and biochemical research on immune disfunction characterization have been published. Advances in this clinical research will broaden current knowledge on depressive moods. The Interleukin-2 soluble receptors determination (Il2sr) is a feasible assay which do not require too much laboratory complexity.
Asunto(s)
Trastorno Depresivo/sangre , Receptores de Interleucina-2/sangre , Anciano , Trastorno Depresivo/diagnóstico , Trastorno Depresivo/psicología , Manual Diagnóstico y Estadístico de los Trastornos Mentales , Ensayo de Inmunoadsorción Enzimática , Humanos , Persona de Mediana Edad , Índice de Severidad de la Enfermedad , Encuestas y CuestionariosRESUMEN
Even though over more than 20 years researchers link different moods and immune function, since 1995 biologic and biochemical research on immune disfunction characterization have been published. Advances in this clinical research will broaden current knowledge on depressive moods. The Interleukin-2 soluble receptors determination (Il2sr) is a feasible assay which do not require too much laboratory complexity.
RESUMEN
Even though over more than 20 years researchers link different moods and immune function, since 1995 biologic and biochemical research on immune disfunction characterization have been published. Advances in this clinical research will broaden current knowledge on depressive moods. The Interleukin-2 soluble receptors determination (Il2sr) is a feasible assay which do not require too much laboratory complexity.